<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616121</url>
  </required_header>
  <id_info>
    <org_study_id>0037-12-HYMC</org_study_id>
    <nct_id>NCT01616121</nct_id>
  </id_info>
  <brief_title>Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well-known that 20-25% of patients hospitalized for acute myocardial infarction will
      develop acute heart failure during their hospitalization. Currently, the investigators have
      no reliable parameter for prediction of evolving acute heart failure in such a group of
      patients. As a result, the investigators have no way of preventing acute heart failure.
      Treatment of these patients only begins after appearance of clinical signs of acute heart
      failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of
      evolving acute heart failure. This study will attempt to address whether preemptive lung
      impedance-guided therapy may prevent the development of overt acute heart failure and improve
      their clinical outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2002</start_date>
  <completion_date type="Actual">July 1, 2014</completion_date>
  <primary_completion_date type="Actual">July 1, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this study the interventional group was treated preemptively according to the lung-impedance protocol and the control group was treated only according to clinical assessment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of acute heart failure development in acute MI patients</measure>
    <time_frame>Three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of clinical outcome in patients with lung impedance-guided treatments</measure>
    <time_frame>Three years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">654</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Conventional Treatment Heart Failure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung Impedance-Guided Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lung Impedance-Guided Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual treatment of patients with developing acute heart failure</intervention_name>
    <arm_group_label>Conventional Treatment Heart Failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lung Impedance-Guided Therapy</intervention_name>
    <description>Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)</description>
    <arm_group_label>Lung Impedance-Guided Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized in the ICCU for acute myocardial infarction and developing acute
             heart failure

        Exclusion Criteria:

          -  Patients with acute myocardial infarction with clinical and radiological signs of
             acute heart failure at admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

